Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00375193 | Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | completed | Phase 2 | 75 | CelgeneINDUSTRY | 3 | Oct 24, 2019 | clinicaltrials |
| NCT00647426 | Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC | completed | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03544814 | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression | completed | Phase 2 | 99 | Shanghai Chest HospitalOTHER | 0 | Oct 15, 2019 | clinicaltrials |
| NCT01754909 | Mitigation of Radiation Pneumonitis and Fibrosis | completed | Phase 2 | 50 | VA Office of Research and DevelopmentFED | 1 | Oct 8, 2019 | clinicaltrials |
| NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma(NGR007) | completed | Phase 2 | 28 | AGC Biologics S.p.A.INDUSTRY | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01165021 | A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer | completed | Phase 2 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT00775307 | Adjuvant Pazopanib in Stage I NSCLC | completed | Phase 2 / Phase 3 | 142 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01281124 | Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01232452 | A Study in Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 20, 2019 | clinicaltrials |
| NCT00349089 | Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy | completed | Phase 2 | 132 | Thoraxklinik-Heidelberg gGmbHOTHER | 3 | Sep 19, 2019 | clinicaltrials |
| NCT00096226 | Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 60 | Radiation Therapy Oncology GroupNETWORK | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01900652 | A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants(Chime) | completed | Phase 2 | 111 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 18, 2019 | clinicaltrials |
| NCT00988858 | A Study of Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 55 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 17, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT01160744 | A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 280 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 13, 2019 | clinicaltrials |
| NCT02115958 | The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine | completed | Phase 1 / Phase 2 | 40 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02425748 | Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation) | completed | Phase 1 / Phase 2 | 40 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02448303 | Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer(KEYNOTE166) | completed | Phase 2 | 74 | Acerta Pharma BVINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02843815 | Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02845856 | Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03007875 | High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01107444 | Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 180 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 11, 2019 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01469000 | A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 195 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 10, 2019 | clinicaltrials |
| NCT03228277 | Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA | completed | Phase 2 | 25 | Konkuk University Medical CenterOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT00126581 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01433172 | Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer | completed | Phase 1 / Phase 2 | 73 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT01439568 | A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01543672 | Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously(VOLUMES) | completed | Phase 1 / Phase 2 | 62 | The Netherlands Cancer InstituteOTHER | 4 | Jun 27, 2019 | clinicaltrials |
| NCT00065182 | Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer | completed | Phase 2 | 399 | GlaxoSmithKlineINDUSTRY | 3 | Jun 24, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT00234052 | Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 51 | Northwestern UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT00554463 | G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer | completed | Phase 2 | 5 | Radiation Therapy Oncology GroupNETWORK | 1 | May 29, 2019 | clinicaltrials |
| NCT00198367 | Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 120 | Hospices Civils de LyonOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT00548093 | PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib | completed | Phase 2 | 66 | PfizerINDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT01866410 | Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 16, 2019 | clinicaltrials |
| NCT03059797 | Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | completed | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT00003231 | Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 2 | 40 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00030810 | Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC | completed | Phase 2 | 46 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00354549 | Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC | completed | Phase 2 | 104 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT01263782 | BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00387465 | Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | May 9, 2019 | clinicaltrials |
| NCT00407550 | Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 19 | Mayo ClinicOTHER | 1 | May 2, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Oct 24, 2019source: clinicaltrials